Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial

  1. Christopoulos, Petros
  2. Bozorgmehr, Farastuk
  3. Brückner, Lena
  4. Chung, Inn
  5. Krisam, Johannes
  6. Schneider, Marc A.
  7. Stenzinger, Albrecht
  8. Eickhoff, Regina
  9. Mueller, Daniel W.
  10. Thomas, Michael ORCID logo

Download
s12885-021-08460-w.pdf 755,72KB
WeightNameValue
1000 Titel
  • Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial
1000 Autor/in
  1. Christopoulos, Petros |
  2. Bozorgmehr, Farastuk |
  3. Brückner, Lena |
  4. Chung, Inn |
  5. Krisam, Johannes |
  6. Schneider, Marc A. |
  7. Stenzinger, Albrecht |
  8. Eickhoff, Regina |
  9. Mueller, Daniel W. |
  10. Thomas, Michael |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-06-28
1000 Erschienen in
1000 Quellenangabe
  • 21(1):743
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12885-021-08460-w |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240323/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Background!#!Availability of potent anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI) has pushed the median survival of ALK!##!Methods/design!#!In this exploratory prospective phase II clinical trial, newly diagnosed ALK!##!Discussion!#!Besides supporting therapeutic decisions for enrolled patients, the ABP trial primarily aims to deepen the understanding of the underlying biology and facilitate development of a framework for individualized management of ALK!##!Trial registration!#!Clinicaltrials.gov , NCT04318938. Registered March 182,020, https://www.clinicaltrials.gov/ct2/show/NCT04318938 Eudra-CT, 2019-001828-36. Registered September 302,019, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-001828-36.
1000 Sacherschließung
lokal Carcinoma, Non-Small-Cell Lung/pathology [MeSH]
lokal Pyrimidines/pharmacology [MeSH]
lokal Anaplastic lymphoma kinase
lokal Protein Kinase Inhibitors/pharmacology [MeSH]
lokal Study Protocol
lokal Humans [MeSH]
lokal Prospective Studies [MeSH]
lokal Protein Kinase Inhibitors/therapeutic use [MeSH]
lokal Brigatinib
lokal Tyrosine kinase inhibitors (TKI)
lokal Medical and radiation oncology
lokal Non-small cell lung cancer
lokal Organophosphorus Compounds/pharmacology [MeSH]
lokal Pyrimidines/therapeutic use [MeSH]
lokal Anaplastic Lymphoma Kinase/drug effects [MeSH]
lokal Molecular risk
lokal ALK
lokal Lung Neoplasms/pathology [MeSH]
lokal Resistance mutations
lokal Phenotype [MeSH]
lokal Carcinoma, Non-Small-Cell Lung/drug therapy [MeSH]
lokal Lung Neoplasms/drug therapy [MeSH]
lokal Organophosphorus Compounds/therapeutic use [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/Q2hyaXN0b3BvdWxvcywgUGV0cm9z|https://frl.publisso.de/adhoc/uri/Qm96b3JnbWVociwgRmFyYXN0dWs=|https://frl.publisso.de/adhoc/uri/QnLDvGNrbmVyLCBMZW5h|https://frl.publisso.de/adhoc/uri/Q2h1bmcsIElubg==|https://frl.publisso.de/adhoc/uri/S3Jpc2FtLCBKb2hhbm5lcw==|https://frl.publisso.de/adhoc/uri/U2NobmVpZGVyLCBNYXJjIEEu|https://frl.publisso.de/adhoc/uri/U3RlbnppbmdlciwgQWxicmVjaHQ=|https://frl.publisso.de/adhoc/uri/RWlja2hvZmYsIFJlZ2luYQ==|https://frl.publisso.de/adhoc/uri/TXVlbGxlciwgRGFuaWVsIFcu|https://orcid.org/0000-0001-9511-055X
1000 Hinweis
  • DeepGreen-ID: 96a5884e18f943acb972fa60c5f483d9 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6462817.rdf
1000 Erstellt am 2023-11-15T14:44:11.062+0100
1000 Erstellt von 322
1000 beschreibt frl:6462817
1000 Zuletzt bearbeitet Thu Nov 30 20:30:29 CET 2023
1000 Objekt bearb. Thu Nov 30 20:30:29 CET 2023
1000 Vgl. frl:6462817
1000 Oai Id
  1. oai:frl.publisso.de:frl:6462817 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source